Register entry
- Registered sites
- 0
- Active NDC listings
- 37
- Labeller names
- 2
- Live patents
- 0
- Countries
- 0
Catalogue
Drug listings by form and route
3737 active NDC listings: 26 human prescription drug, 10 drug for further processing, 1 cellular therapy. By marketing category: NDA 24, DRUG FOR FURTHER PROCESSING 10, BLA 3.
| Dosage form | NDCs |
|---|---|
| capsule | 26 |
| tablet, film coated | 4 |
| injection, powder, lyophilized, for solution | 3 |
| kit | 3 |
| suspension | 1 |
| Route | NDCs |
|---|---|
| oral | 20 |
| subcutaneous | 3 |
| intravenous | 2 |
| Labeller name on the listing | NDCs |
|---|---|
| celgene corporation | 30 |
| celgene international sarl | 7 |
Catalogue
Marketed products
37| Brand | Generic name | Form / route | NDC |
|---|---|---|---|
| Abecma | idecabtagene vicleucel | suspension, intravenous | 59572-515BLA |
| ISTODAX | romidepsin | kit | 59572-984NDA |
| Idhifa | enasidenib mesylate | tablet, film coated, oral | 59572-705NDA |
| Idhifa | enasidenib mesylate | tablet, film coated, oral | 59572-710NDA |
| Inrebic | Fedratinib Hydrochloride | capsule, oral | 59572-720NDA |
| ONUREG | azacitidine | tablet, film coated, oral | 59572-730NDA |
| ONUREG | azacitidine | tablet, film coated, oral | 59572-740NDA |
| Pomalyst | pomalidomide | capsule, oral | 59572-501NDA |
| Pomalyst | pomalidomide | capsule, oral | 59572-502NDA |
| Pomalyst | pomalidomide | capsule, oral | 59572-503NDA |
| Pomalyst | pomalidomide | capsule, oral | 59572-504NDA |
| Reblozyl | Luspatercept | injection, powder, lyophilized, for solution, subcutaneous | 59572-711BLA |
| Reblozyl | Luspatercept | injection, powder, lyophilized, for solution, subcutaneous | 59572-775BLA |
| Revlimid | Lenalidomide | capsule, oral | 59572-402NDA |
| Revlimid | Lenalidomide | capsule, oral | 59572-405NDA |
| Revlimid | Lenalidomide | capsule, oral | 59572-410NDA |
| Revlimid | Lenalidomide | capsule, oral | 59572-415NDA |
| Revlimid | Lenalidomide | capsule, oral | 59572-420NDA |
| Revlimid | Lenalidomide | capsule, oral | 59572-425NDA |
| Thalomid | Thalidomide | capsule, oral | 59572-205NDA |
| Thalomid | Thalidomide | capsule, oral | 59572-210NDA |
| Thalomid | Thalidomide | capsule, oral | 59572-215NDA |
| Thalomid | Thalidomide | capsule, oral | 59572-220NDA |
| - | Thalomide Capsule | capsule | 43593-205DRUG FOR FURTHER PROCESSING |
| - | Thalomide Capsule | capsule | 43593-210DRUG FOR FURTHER PROCESSING |
| - | Thalomide Capsule | capsule | 43593-215DRUG FOR FURTHER PROCESSING |
| - | Thalomide Capsule | capsule | 43593-220DRUG FOR FURTHER PROCESSING |
| VIDAZA | azacitidine | injection, powder, lyophilized, for solution, intravenous, subcutaneous | 59572-102NDA |
| ZEPOSIA | ozanimod hydrochloride | capsule, oral | 59572-820NDA |
| ZEPOSIA 7-Day Starter Pack | ozanimod hydrochloride | kit | 59572-810NDA |
| ZEPOSIA Starter Kit | ozanimod hydrochloride | kit | 59572-890NDA |
| - | ozanimod hydrochloride | capsule | 43593-800DRUG FOR FURTHER PROCESSING |
| - | ozanimod hydrochloride | capsule | 43593-801DRUG FOR FURTHER PROCESSING |
| - | ozanimod hydrochloride | capsule | 43593-803DRUG FOR FURTHER PROCESSING |
| - | ozanimod hydrochloride | capsule | 59572-812DRUG FOR FURTHER PROCESSING |
| - | ozanimod hydrochloride | capsule | 59572-814DRUG FOR FURTHER PROCESSING |
| - | ozanimod hydrochloride | capsule | 59572-816DRUG FOR FURTHER PROCESSING |
Enquiry
Common questions
- Is Celgene International Sarl FDA approved?
- Celgene International Sarl holds no registered establishment of its own; 37 drug products are listed under its name in the National Drug Code Directory, made at sites registered to other firms.
- What drugs does Celgene International Sarl make?
- 37 products are listed under Celgene International Sarl in the openFDA NDC Directory, most often as capsule; tablet, film coated; injection, powder, lyophilized, for solution. The full breakdown by dosage form and route is above. A listing count is not a sales figure.
Compiled from FDA establishment registrations, the openFDA NDC Directory, the Orange Book and the FDA drug shortage database. Not claimed by the company. Sources and methodology.